初创公司ProFuse推出用于预防肌肉损失的开创性药物发现平台-动脉网

Startup ProFuse Launches Pioneering Drug Discovery Platform for the Prevention of Muscle Loss

CISION 等信源发布 2025-04-03 20:14



可切换为仅中文







YOKNEAM ILLIT, Israel

以色列约克尼姆伊里特

，

April 3, 2025

2025年4月3日

/PRNewswire/ -- Israeli startup

/PRNewswire/ -- 以色列初创公司

ProFuse Technology

ProFuse技术

, which specializes in the cultivation of muscle tissue in laboratory conditions, has launched a new technology and program for discovering drugs that prevent muscle mass loss caused by the growing use of

专门从事在实验室条件下培育肌肉组织的公司，推出了一项新技术和计划，用于发现防止因不断使用而导致肌肉质量下降的药物。

GLP-1

weight-loss injections, aging, and cancer.

减肥注射、衰老和癌症。

ProFuse's technology is based on developing methods to generate highly mature muscle tissues that accurately reflect the structure and function of natural human muscle. The company is now applying this technology to discover new drug candidates and to predict with high accuracy which molecules have the potential to gain regulatory approval as new therapies for preventing and restoring muscle mass..

ProFuse的技术基于开发生成高度成熟肌肉组织的方法，这些组织能够准确反映天然人体肌肉的结构和功能。该公司现在正在应用这项技术来发现新的候选药物，并高精度预测哪些分子有潜力作为预防和恢复肌肉质量的新疗法获得监管批准。

The process utilizes advanced automation to efficiently screen potential drug candidates. This represents a breakthrough compared to existing technologies, which rely on conventional models with limited predictive power—necessitating extensive animal testing. ProFuse's technology enables precise testing of a large number of molecules, thereby streamlining the research process and significantly reducing time, resources, and costs..

该过程利用先进的自动化技术高效筛选潜在的药物候选物。与现有技术相比，这是一项突破，现有技术依赖预测能力有限的传统模型，需要进行大量的动物实验。ProFuse的技术能够对大量分子进行精确测试，从而简化研究过程，大幅节省时间、资源和成本。

The demand for muscle-preserving therapies is rapidly increasing.

对保持肌肉的疗法的需求正在迅速增加。

GLP-1

weight-loss treatments are

减肥治疗是

expected

预期

to grow significantly by 2030, but unintended muscle loss associated with these drugs poses a significant health concern.

到 2030 年将显著增长，但这些药物相关的非预期肌肉损失构成了严重的健康问题。

Another key area for muscle preservation drugs is sarcopenia, or age-related muscle loss, which

肌肉保存药物的另一个关键领域是肌肉减少症，或与年龄相关的肌肉损失， которые

affects

影响

approximately 10% to 16% of individuals over 50—equating to around 13 million to 20 million Americans. Sarcopenia contributes to increased frailty and is linked to significant healthcare costs. Additionally, a major indication for such therapies is cancer cachexia, a condition affecting a growing number of advanced-stage cancer patients.

大约10%到16%的50岁以上个体——相当于约1300万到2000万美国人。肌肉减少症会增加身体虚弱，并与高额的医疗成本相关。此外，此类疗法的一个主要适应症是癌症恶病质，这一病症影响着越来越多的晚期癌症患者。

Cancer cachexia leads to severe muscle wasting, physical decline, and reduced treatment success..

癌症恶病质会导致严重的肌肉萎缩、身体机能下降以及治疗效果降低。

ProFuse was founded in 2021 by Professor

ProFuse 由教授于2021年创立。

Eldad Tzahor

艾尔达德·查霍尔

and Dr.

和博士。

Tamar Eigler-Hirsh

塔玛·艾格勒-赫什

from the Weizmann Institute of Science (CTO), along with

来自魏茨曼科学研究所（CTO），以及

Guy Nevo-Michrowski

盖伊·内沃-米赫罗夫斯基

, who serves as the company's CEO. Dr. Eigler-Hirsh and Prof. Tzahor, in collaboration with Dr.

，他担任公司的首席执行官。艾格勒-赫希博士和扎霍尔教授与博士合作。

Ori Avinoam

奥里·阿维诺姆

, identified the natural process responsible for muscle regeneration and repair. This discovery paved the way for the development of an innovative technology that enables the efficient cultivation of highly mature muscle fibers under laboratory conditions.

，确定了负责肌肉再生和修复的自然过程。这一发现为开发创新技术铺平了道路，使得在实验室条件下高效培养高度成熟的肌纤维成为可能。

Over four years, this technology positioned ProFuse as a leading company in the global cultivated meat industry. Two years ago, ProFuse began leveraging its muscle cultivation technology for additional applications, and it has recently expanded into drug discovery

四年时间里，这项技术使ProFuse成为全球培养肉行业的领先公司。两年前，ProFuse开始将其肌肉培养技术应用于其他领域，并且最近扩展到了药物发现领域。

ProFuse also announces today the appointment of Anat Naschitz to its Board of Directors. Naschitz is a prominent investor and entrepreneur in the life sciences field, with nearly 30 years of experience in founding, managing, and investing in companies and venture capital funds. Throughout her career, she has collaborated with leading industry players, from major pharmaceutical companies to cutting-edge biotech firms.

ProFuse今天还宣布任命Anat Naschitz为其董事会成员。Naschitz是生命科学领域的知名投资者和企业家，拥有近30年创立、管理和投资公司及风险投资基金的经验。在她的职业生涯中，她与从大型制药公司到前沿生物技术公司的领先行业参与者均有合作。

Notably, Naschitz co-founded and co-led OrbiMed Israel, part of the global healthcare investment firm managing approximately .

值得注意的是，纳施茨共同创立并共同领导了奥比梅德以色列，该公司是全球医疗保健投资公司的一部分，管理着大约。

$20 billion

200亿美元

。

Anat Naschitz: 'I am grateful to ProFuse for the opportunity to be part of the journey in discovering and developing drugs that prevent muscle mass loss —an important clinical need requiring a solution. I was impressed by the company's and management's ability to demonstrate resilience in the face of challenges requiring adaptation and change.

阿纳特·纳希茨：“我很感激ProFuse给我机会参与发现和开发预防肌肉质量流失的药物之旅——这是一个需要解决方案的重要临床需求。公司的管理层面对需要适应和改变的挑战时所展现出的韧性让我印象深刻。

This adaptability was evident both at the industry level—strategically pivoting toward new directions—and at the operational level, where the company exhibited remarkable flexibility, strategic decision-making, and an unwavering positive spirit.'.

这种适应性在行业层面和运营层面都表现得非常明显——在行业层面，公司战略性地转向新的方向；在运营层面，公司展现出非凡的灵活性、战略决策能力以及坚定不移的积极精神。

'ProFuse's timing for entering the market is excellent,' said

“ProFuse进入市场的时间非常出色，”

Guy Nevo-Michrowski

盖伊·内沃-米赫罗夫斯基

, CEO and co-founder of the company. 'Weight-loss drugs lead to muscle mass loss, prompting pharmaceutical companies to invest significant resources in developing innovative treatments that combine

，公司首席执行官兼联合创始人。“减肥药物会导致肌肉质量下降，促使制药公司投入大量资源开发创新疗法结合

GLP-1

weight-loss drugs with muscle mass preservation therapies. As a result, several major deals in the muscle preservation drug sector have been signed in recent years, with transaction values reaching several billion dollars. This trend signals a significant window of opportunity for new technologies in this field, including ours.'.

减肥药物与肌肉质量保存疗法相结合。因此，近年来在肌肉保存药物领域已经签署了若干重大协议，交易价值达到数十亿美元。这一趋势表明，该领域的新技术，包括我们的技术，面临着一个重要的机遇窗口。

ProFuse was established under the Fresh Start incubator and has raised approximately

ProFuse 在 Fresh Start 孵化器下成立，并已筹集了大约

$8 million

800万美元

to date, including

迄今为止，包括

$3 million

300万美元

in grants from the European Union and the Israel Innovation Authority, as well as

来自欧盟和以色列创新局的拨款，以及

$5 million